Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Steveminon Mar 09, 2021 2:32pm
234 Views
Post# 32754370

H.C. Wainwright presentation this morning

H.C. Wainwright presentation this morningNot sure how many of you listened to this presentation, but take a listen around the 27:00 mark. 
Adams was talking about Integrasyn and scaling up batch production. Here's what he said:

"This is a very very expensive step, so unless we have a particular need for the final product, we may chose to delay this until such a time that we or another person needs this pharmaceutical grade product".

Wait. What? Inmed has spent literally years of time, tens of millions of dollars and tons of resources to reach this point and all the sudden they think that "scale up" is too expensive??? He said a couple of years ago that people were beating down his door for cannabinoids and wanted to buy them in buckets and now all of the sudden he is just going to delay scale up? This makes absolutely no sense. There is a WIDE OPEN market for cannabinoid testing and if they have figured out how to optimize the pathway with Integrasyn, then they should be receiving purchase orders daily. This makes absolutely no sense. 

He is basically taking away the only path to revenue for Inmed.
EB and Glaucoma are 5-7 years away from potential monetization.

This is a real curious move on his part. Guess we now know why he jumped at that $4M placement recently - he knows when the next time comes around for a cash raise, he may have to dilute 50% because the sp will be even further depressed. As a stock holder, I am outraged...
<< Previous
Bullboard Posts
Next >>